Abstract:Abstract Background Lipoproteins were associated with sepsis related mortality because of their critical role in immune-inflammatory modulation and pathogen sequestration. Cholesteryl ester transfer protein (CETP), a lipid-modifying drug target, was reported to be associated with sepsis in recent animal models. However, whether there was a causal effect of inhibition of CETP on reducing the risk of sepsis and severe pneumonia for patients in critical care being still unknown. Therefore, we estimated the causal association of genetically proxied inhibition of CETP, along with high-density and low-density lipoprotein cholesterol directly, with the risk of sepsis, pneumonia and 28-day mortality in critical care. Methods The genotype of sepsis and pneumonia cohorts (N 431,365) were obtained from multi-center biobanks throughout the United Kingdom between 2006 and 2010. Single-nucleotide polymorphisms (SNPs) in CETP associated with circulating high-density lipoprotein cholesterol in a genome-wide association study (GWAS) (N 188,577) were used to proxy inhibition of CETP. We also conducted genetically proxied other three commonly lipid-modifying drug targets (3-hydroxy-3-methylglutaryl coenzyme A reductase, proprotein convertase subtilisin/kexin type 9, and Niemann-Pick C1-Like 1) using a similar method. A drug-target Mendelian randomization framework with inverse-variance weighted method was used to assess the causal association. Results Genetically proxied inhibition of CETP was significantly associated with lower risk of sepsis (odds ratio [OR], 0.83 [95% CI, 0.73–0.95]; P = 0.005), pneumonia (OR, 0.78 [95% CI, 0.72–0.86]; P = 1.46e-07) and lower 28-day mortality from sepsis in critical care (OR, 0.68 [95% CI, 0.52–0.87]; P = 0.003). There was no significant evidence of direct association of genetically proxied high-density and low-density lipoprotein cholesterol levels, and other commonly lipid-modifying drug targets with sepsis, pneumonia and 28-day mortality in critical care. Conclusion Our findings support a causal effect of genetically proxied inhibition of CETP on lower risk of sepsis, severe pneumonia, and sepsis related mortality in critical care. This effect seems to be mechanism-specific, independent of circulating high-density lipoprotein cholesterol levels. However, whether pharmaceutical CETP inhibitors could be a promising strategy for sepsis prevention and treatment remained further clinical trials.

Therapeutic potential of procathepsin L-inhibiting and progesterone-entrapping dimethyl-β-cyclodextrin nanoparticles in treating experimental sepsis

Development of Procathepsin L (pCTS-L)-Inhibiting Lanosterol-Carrying Liposome Nanoparticles to Treat Lethal Sepsis

Identification of procathepsin L (pCTS-L)-neutralizing monoclonal antibodies to treat potentially lethal sepsis

Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management

Precise engineering of neutrophil membrane coated with polymeric nanoparticles concurrently absorbing of proinflammatory cytokines and endotoxins for management of sepsis

ICAM-1-targeted and Antibacterial Peptide Modified Polymeric Nanoparticles for Specific Combating Sepsis

Bioengineered Stem Cell Membrane Functionalized Nanoparticles Combine Anti-Inflammatory and Antimicrobial Properties for Sepsis Treatment

Thymopentin Improves the Survival of Septic Mice by Promoting the Production of 15‐deoxy‐prostaglandin J2 and Activating the PPARγ Signaling Pathway

Augmenting Neutrophil Extracellular Traps with Carbonized Polymer Dots: A Potential Treatment for Bacterial Sepsis

Robust and Multifunctional Therapeutic Nanoparticles against Peritonitis-Induced Sepsis

Genetic insights into cholesteryl ester transfer protein as a novel therapeutic target for sepsis and severe pneumonia

Multifunctional Endogenous Small Molecule-Derived Polymer Composite Nanoparticles for the Treatment of Acute Sepsis Therapy

A Cyclodextrin‐based Ph‐Responsive Microrna Delivery Platform Targeting Polarization of M1 to M2 Macrophages for Sepsis Therapy

Cath-HG improves the survival rates and symptoms in LPS-induced septic mice due to its multifunctional properties

Endotoxin-adsorbing Macrophage-Mimetic Hybrid Liposome for Sepsis Treatment

Apoptotic Body Based Biomimetic Hybrid Nanovesicles to Attenuate Cytokine Storms for Sepsis Treatment

Discovery of Novel Pterostilbene Derivatives That Might Treat Sepsis by Attenuating Oxidative Stress and Inflammation Through Modulation of MAPKs/NF-κB Signaling Pathways

Combined Treatment with a CXCL12 Analogue and Antibiotics Improves Survival and Neutrophil Recruitment and Function in Murine Sepsis.

Cell-membrane-coated nanoparticles for the fight against pathogenic bacteria, toxins, and inflammatory cytokines associated with sepsis

Antimicrobial peptide nanoparticles coated with macrophage cell membrane for targeted antimicrobial therapy of sepsis

Protectin DX increases survival in a mouse model of sepsis by ameliorating inflammation and modulating macrophage phenotype